Intarcia Therapeutics, Inc., is a biopharmaceutical company committed to developing innovative therapies utilizing the Medici Drug Delivery System — medicines that have the potential to transform the prevention and management of serious chronic diseases. The company's near-term goal is to deliver a game-changing new level of glycemic control for a vast number of patients with type 2 diabetes. On the other hand, Intarcia's longer-term goal is to expand the Medici Drug Delivery System further into diabetes and obesity treatment, and its prevention, and its new initiative for improved global HIV prevention. Said Medici Drug Delivery System is comprised of three unique technologies:
- A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures for up to three years or more;
- A matchstick-sized osmotic mini-pump that is placed just under the dermal layer of skin to deliver a continuous and consistent flow of medication; and
- A placement technology including proprietary tools designed to provide an optimal user experience.
Select investors Venrock, New Enterprise Associates, New Leaf Venture Partners, The Baupost Group, Farallon Capital Management, Foresite Capital, Franklin Templeton Investments, Alger, Quilvest
Last update: May 13, 2018
Disclaimer: We can not guarantee that the information on this page is 100% correct. more